- Not Yet Recruiting
- Prevention
- Interventional
- Randomized
- Behavioral
- University of Toronto
- -
Study Purpose
The primary aim of this study is to compare the acute glycemic effects of two novel, alternative physical activity (PA) strategies (dispersed post-meal PA, PA snacks) to a no PA condition and to exercise sessions representing the PA guidelines (standard 30-minute walking bout performed under fasting and under postprandial conditions and a standard 30-minute resistance training session) among sedentary survivors of breast and prostate cancer who are currently receiving hormone therapies. The secondary aim is to determine whether the alternative PA strategies are acceptable and feasible in the free-living setting. The exploratory aim is to determine whether these outcomes differ by cancer type. The investigators hypothesize that: 1. Dispersed PA and PA snacks will result in greater reductions in 24-hour glucose and postprandial glucose compared to the no-PA baseline and similar reductions to a standard 30-minute bouts of walking; 2. The alternative PA strategies will be more feasible and have greater acceptability by cancer survivors compared to the standard 30-minute bout of walking or resistance training; and 3. The different PA strategies will have similar effects on glycemic outcomes for both breast and prostate cancer survivors. The resistance exercise session is an exploratory trial as the effects of it on acute glycemic control are understudied.
Intervention
Behavioral : Standard Physical Activity - Fasted
Behavioral : Standard Physical Activity - Post-Meal
Behavioral : Dispersed Physical Activity
Behavioral : Physical Activity Snacks
Behavioral : Muscle Strengthening
Eligibility Requirements
Postmenopausal biological females diagnosed with stage I, II, or III breast cancer and currently using aromatase inhibitors (AI)
Biological males diagnosed with stage I, II, or III prostate cancer and currently using androgen deprivation therapy (ADT).
All participants must meet the following criteria:
* Taking AI or ADT for at least 3 months prior to start of study participation.
* Body mass index equal to or greater than 25 kg/m\^2.
* Self-report consuming three main meals daily.
* Self-report as being sedentary (i.e., less than 30 minutes/week of moderate-to-vigorous aerobic physical activity and less than twice/week muscle strengthening of major muscle groups in the last three months.
Minimum age: 18
If unable or unwilling to receive medical clearance by a physician after being screened for major signs or symptoms of cardiovascular diseases, diabetes, or renal disease and safety to initiate exercise.
* Major signs or symptoms of cardiovascular diseases, diabetes, or renal disease are taken from the American College of Sports Medicine's Guidelines for Exercise Testing and Prescription 11th edition Table 2.1. They include pain or discomfort in the chest, neck, jaw, arms with rest or exercise, shortness of breath at rest or with mild exertion, dizziness or syncope, ankle edema, palpitations or tachycardia, intermittent claudication, known heart murmur, and unusual fatigue with usual activities.
* Safety to initiate exercise will be screened using the Get Active Questionnaire, which is the Canadian Society of Exercise Physiology's endorsed evidence-based pre-screening tool
Using drugs for diabetes management (e.g., exogenous insulin, Ozempic, metformin, etc.) or actively losing weight (i.e., \>5 kg weight loss in past 3 months) from drugs or other reasons
Report any injury or other reason for not feeling capable of completing a 30 minute continuous walk or muscle strengthening exercise
Unable to access an Ontario Lifelabs location for an overnight fasted blood draw
Do not have a smartphone compatible with the applications required to collect data.
Cannot read and understand the consent form or communicate in English.
Recruiting status
Not Yet Recruiting
Estimated enrollment
24
Study start date
Oct 15, 2024
Study end date
Mar 01, 2025
Last updated
Mar 23, 2025
Primary purpose
Prevention
Design
Interventional
Intervention
Behavioral
Study phase
NA
Allocation
Randomized
Sponsor:
University of Toronto
Collaborator:
N/A
Investigator:
N/A
Publications
N/A
Websites
N/A
NCT06633380
Clinic | Location | Investigator | Distance | RECRUITING STATUS | Contact |
---|